1. Home
  2. PHR vs TRVI Comparison

PHR vs TRVI Comparison

Compare PHR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phreesia Inc.

PHR

Phreesia Inc.

HOLD

Current Price

$12.26

Market Cap

713.2M

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$12.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHR
TRVI
Founded
2005
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.2M
1.5B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PHR
TRVI
Price
$12.26
$12.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
12
Target Price
$30.65
$20.38
AVG Volume (30 Days)
2.0M
1.2M
Earning Date
03-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
59.36
N/A
EPS
0.02
N/A
Revenue
$419,813,000.00
N/A
Revenue This Year
$15.56
N/A
Revenue Next Year
$15.08
N/A
P/E Ratio
$614.75
N/A
Revenue Growth
17.83
N/A
52 Week Low
$11.31
$4.22
52 Week High
$32.76
$14.39

Technical Indicators

Market Signals
Indicator
PHR
TRVI
Relative Strength Index (RSI) 38.70 66.39
Support Level $11.58 $11.91
Resistance Level $12.79 $14.39
Average True Range (ATR) 0.64 0.65
MACD 0.18 0.20
Stochastic Oscillator 64.19 89.66

Price Performance

Historical Comparison
PHR
TRVI

About PHR Phreesia Inc.

Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: